open access

Vol 44, No 5 (2010)
ARTYKUŁ ORYGINALNY
Submitted: 2010-03-09
Get Citation

Neuron-specific enolase and S 100B protein as predictors of outcome in ischaemic stroke

Małgorzata Kaca-Oryńska, Ryszard Tomasiuk, Andrzej Friedman
DOI: 10.1016/S0028-3843(14)60136-5
·
Neurol Neurochir Pol 2010;44(5):459-463.

open access

Vol 44, No 5 (2010)
ARTYKUŁ ORYGINALNY
Submitted: 2010-03-09

Abstract

Background and purpose

As neuron-specific enolase (NSE) and S 100B protein are brain origin proteins, the aim of this study was to assess whether a single NSE and S 100B measure may predict clinical outcome of patients with cerebral ischaemic infarct.

Material and methods

Seventy-one patients with ischaemic stroke and 41 controls were studied. All patients had computed tomography of the brain performed after admission and on the third day and volume of the infarct was assessed by the volumetric method from the second examination. NSE and S 100B protein were analysed by immunochemiluminescence on the fourth day after admission. Clinical state of the patients was determined with the NIH stroke, Barthel and Rankin scales on admission, discharge from the hospital, and after one and 3 months from the onset of stroke.

Results

NSE levels in blood were significantly higher in stroke patients than in the control group – 36.9 ± 24.0 vs. 14.3 ± 9.7 μg/L. Also, the levels of the S 100B protein were significantly higher in the patient group (0.85 ± 1.74 vs. 0.10 ± 0.03 μg/L) but only the levels of S 100B protein correlated with the calculated size of the infarct (Spearman coefficient = 0.77). No such correlation was identified for NSE level (Spearman coefficient = 0.25).

Conclusions

Although significant differences in NSE and S 100B levels between stroke patients and the control group were found, only S 100B protein level correlated with stroke volume, neurological status at admission and functional outcome. NSE did not correlate with stroke volume, neurological status or clinical outcome.

Abstract

Background and purpose

As neuron-specific enolase (NSE) and S 100B protein are brain origin proteins, the aim of this study was to assess whether a single NSE and S 100B measure may predict clinical outcome of patients with cerebral ischaemic infarct.

Material and methods

Seventy-one patients with ischaemic stroke and 41 controls were studied. All patients had computed tomography of the brain performed after admission and on the third day and volume of the infarct was assessed by the volumetric method from the second examination. NSE and S 100B protein were analysed by immunochemiluminescence on the fourth day after admission. Clinical state of the patients was determined with the NIH stroke, Barthel and Rankin scales on admission, discharge from the hospital, and after one and 3 months from the onset of stroke.

Results

NSE levels in blood were significantly higher in stroke patients than in the control group – 36.9 ± 24.0 vs. 14.3 ± 9.7 μg/L. Also, the levels of the S 100B protein were significantly higher in the patient group (0.85 ± 1.74 vs. 0.10 ± 0.03 μg/L) but only the levels of S 100B protein correlated with the calculated size of the infarct (Spearman coefficient = 0.77). No such correlation was identified for NSE level (Spearman coefficient = 0.25).

Conclusions

Although significant differences in NSE and S 100B levels between stroke patients and the control group were found, only S 100B protein level correlated with stroke volume, neurological status at admission and functional outcome. NSE did not correlate with stroke volume, neurological status or clinical outcome.

Get Citation

Keywords

neuron-specific enolase, S 100B protein, stroke, predictors

About this article
Title

Neuron-specific enolase and S 100B protein as predictors of outcome in ischaemic stroke

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 44, No 5 (2010)

Pages

459-463

DOI

10.1016/S0028-3843(14)60136-5

Bibliographic record

Neurol Neurochir Pol 2010;44(5):459-463.

Keywords

neuron-specific enolase
S 100B protein
stroke
predictors

Authors

Małgorzata Kaca-Oryńska
Ryszard Tomasiuk
Andrzej Friedman

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl